The advent of immune checkpoint inhibitors (ICIs) has marked a paradigm shift in cancer treatment, yet a significant portion of breast cancer patients fail to respond to these therapies.
Background The widespread mobilisation to improve maternal health over recent decades has led to increased prenatal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results